At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Minocycline +1 moredrug
Likely dose
Minocycline 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Placebo and Minocycline for Myeloma. Completed, enrolled 79 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to see if Minocin® (minocycline) can help to control nerve damage that causes numbness and tingling in the hands and feet (neuropathy) in patients receiving thalidomide and/or bortezomib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyeloma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionAug 2022
TodayJul 2026
First PostedJan 26, 2011
Enrollment StartJan 25, 2011
Primary CompletionAug 22, 2022
TodayJul 2, 2026
Enrollment to primary: 11.6 yearsPosted 15.4 years ago
Interventions
Placeboother
One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
Minocyclinedrug
200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.